Gene transfer complexes containing poly-L-lysine (poly-K) and DNA with ligands directed at the serpin enzyme complex receptor (sec-R) deliver reporter genes to receptor-bearing cells in vivo. Expression lasts for about 30 days, when complexes containing long-chain poly-K are used. Extending the duration of expression would be desirable if correction of genetic defects is the goal. To test whether the mechanism by which expression is extinguished was due to an immune response to the transgene, or the loss of the transgene, we conducted two experiments. In the first, we injected sec-Rtargeted lacZ complexes intravenously (i.v.) into mice genetically engineered to express this gene briefly during development. These mice, who should recognize the protein as 'self', also extinguished lacZ expression after 30 days. In a second experiment, we injected immunodeficient animals with sec-R-targeted human factor IX complexes. A similar temporal pattern of expression was observed in Rag-1 À/À mice, in whom expression also extinguished by 40 days. Moreover, factor IX plasmid DNA was detected in the lung and spleen 50 days after injection of complexes, suggesting that not all cells which had taken up the transgene had been destroyed. Thus, the host's immune response to the transgene may not account for the loss of reporter gene expression from these molecular conjugates. We further tested whether repeat administration of sec-R-targeted complexes will be limited by host immune responses. Mice were pre-dosed twice with sec-R-targeted complexes containing lacZ over a 40-day period. We then injected the animals i.v. with sec-R-targeted human factor IX complexes and measured gene expression and antibody production. Although 14 of 36 animals displayed low-titer antibodies to the ligand in targeted complex, expression levels were unaffected compared with virgin dosing. When the complexes were administered three times intranasally (n ¼ 10), no antibodies against the complex were detected in blood. Plasma from mice dosed with saline, nontargeted complex or naked DNA did not react with the ligand, ligand-poly K conjugate or targeted complex. All animals exhibiting human factor IX expression developed antibodies to that transgene by 21 days. Thus, at least three repeat administrations of sec-R-directed molecular conjugates are possible, provided that immune responses to the transgene itself are not limiting.
Introduction
Receptor-mediated gene transfer of compacted DNA has the advantages of safety, specificity, and the ability to access nondividing cells, but the disadvantages of short duration and relatively low-level expression in vivo. 1 We have used gene transfer complexes directed at the serpin-enzyme complex receptor (sec-R) as a model system to address some of these limitations. This receptor is expressed at high levels in hepatocytes, 2, 3 macrophages, 4 and neurons, 5 as well as the apical surface of airway epithelial cells, 6 has high specificity for a pentapeptide-binding motif but low specificity for the attached cargo, 7 and can be accessed with the same ligands in rat, mouse, and man. 8 The sec-R can be targeted by a short peptide sequence which was included in a peptide ligand, covalently coupled to poly-K, condensed by charge interaction with plasmid DNA under high salt conditions into unimolecular (with respect to DNA) complexes about 20-25 nm in diameter. 2, 8, 9 Earlier studies in human hepatoma cell lines in vitro determined that 10-11 receptor ligands per complex give optimal transfection, 8 and that longer chain length poly-L-lysine (poly K) favored longer duration of expression in vitro and in vivo. 9 However, even with long-chain poly K-containing complexes, expression returned to background levels after about 30 days in vivo. 9 Therefore, to achieve protracted expression, either the decline in expression must be prevented, or the complexes must be readministered.
Preventing the decline in expression will require understanding of the mechanisms that contribute to the decline. We undertook the current studies to determine whether loss of expression was due to the host's immunologic response to the complex components and/or the foreign gene. If immunologic destruction of gene-expressing cells contributes to the decrement in expression, then use of a less immunogenic transgene, or manipulation of immune responses, might be of benefit. If immune destruction of transfected cells is only a minor component of the decrement in expression, then efforts to reengineer the plasmid should be pursued.
We tested two reporter genes, bacterial b-galactosidase (lacZ) and human coagulation factor IX (hFIX), in both wild-type mice and engineered mouse models. In the RARb-2lacZ-FVB/N mice, the bacterial lacZ gene is expressed, under control of the retinoic acid receptor promoter, briefly during development, so that these animals should recognize this protein as 'self' and fail to mount immunologic responses against it; yet, the adult animals do not display endogenous expression of the lacZ gene, which might confuse interpretation of experiments in which this gene is used as a reporter. 10 In Rag-1 À/À mice, the recombination-activating gene, required for the somatic rearrangement of immunoglobulin genes and T-cell receptor genes and the subsequent development of B and T cells, is knocked out. These animals mount neither antibody nor cytotoxic lymphocyte response to foreign protein. These mice have been shown to display protracted expression of a human factor IX transgene compared to immunocompetent mice, largely because the protein can still be detected in the blood in the absence of neutralizing antibodies. 11 Our results indicate that host immune responses to the transgene and/or the complex components are unlikely to explain extinguishing of transgene expression. Since the non-viral vector does not readily integrate into the genome, however, their duration of expression will probably not exceed the life of the transfected cell; so if continuous expression is desired, repeat dosing will be necessary. Therefore, we also tested whether repeat administration of sec-Rtargeted DNA complex results in diminished expression with each dose, as it might if the host response to the complex prevents its subsequent effectiveness in gene delivery.
Results
Dose response for targeted lacZ II DNA complexes in C57BL/6 mice Mice injected intravenously (i.v.) with 2.5, 12.5, or 25 mg of targeted lacZ II DNA complexes all expressed lacZ activity significantly above background in the liver and lung, but not in spleen, 4 days following injection (different from uninjected animals, Po0.05) (Figure 1 ). Reporter gene expression from the three doses did not differ significantly, and the intermediate dose (12. 5 mg of sec-R-targeted lacZ II DNA) was selected for further studies.
Localization of lacZ transgene expression
Following i.v. injections of 12.5 mg DNA of sec-R targeted complexes, X-gal staining revealed expression in tissue macrophages in lung and spleen in all animals. No significant histochemical staining was observed in liver despite measurable enzyme chemiluminescent activity ( Figure 1 ). To test whether this discrepancy is unexpected or consistent with the known threshold effect for X-gal staining of 50-100 000 molecules of lacZ per cell, cultures of HuH7 human hepatoma cells were transfected with varying concentrations of pCMV lacZ II DNA. Assays of duplicate samples revealed that an applied dose of 10 ng DNA is required to detect both chemiluminescent activity and X-gal staining (Table 1) . Although 1, 0.1, and 0.01 ng of DNA resulted in chemiluminescent activity of at least 100 times background, no X-gal staining was achieved.
X-gal staining in lung was observed at 4 (data not shown) and 21 days (Figure 2a ), while in spleen staining was only observed at the later time point (Figure 2b) , consistent with the gene expression data. X-gal staining patterns were similar in C57BL/6 and RARb-2lacZ-FVB/ N mice (photographs of RARb-2lacZ-FVB/N mice are Figure 1 Expression of lacZ 4 days following i.v. injection of sec-Rtargeted complexes in C57BL/6 mice. C57BL/6 mice were injected in the tail vein with sec-R-targeted CMV lacZ II DNA complexes (2.5, 12.5, or 25 mg of DNA). Tissues (N ¼ 8 for each dose) were harvested 4 days following injection and assayed for lacZ activity along with tissues harvested from uninjected animals (N ¼ 6). * Different from uninjected control (Po0.05). Host immunity responses to sec-R-mediated gene transfer A-G Ziady et al Figure 3 Duration of lacZ expression in C57BL/6 and RARb-2lacZ-FVB/N mice. Uninjected C57BL/6 and RARb-2lacZ-FVB/N mice and mice receiving nontargeted and sec-R-targeted CMV lacZ II DNA complexes (12.5 mg) were killed at intervals following injection and their tissues examined for lacZ activity. Each treatment group at each time point contained five to seven animals. Panel a: C57BL/6 animals, injected with sec-R-directed lacZ complexes and uninjected controls; panel b: C57BL/6 animals, injected with nontargeted lacZ complexes and uninjected controls; panel c: RARb-2lacZ-FVB/N mice injected with sec-R-targeted lacZ complexes and uninjected controls; panel d: RARb-2lacZ-FVB/N mice injected with nontargeted complexes and uninjected controls. *Different from uninjected control (Po0.05). Localization of lacZ expression in C57BL/6 mice. At 21 days after injections (12.5 mg DNA content) of sec-R-targeted, nontargeted, and naked CMV lacZ II DNA, mice (four per group) were killed and their organs assessed for lacZ expression by X-gal staining. Panels display representative images of: SEC-R-targeted lacZ activity in lung (a), and spleen (b); nontargeted lacZ activity in lung (c), and spleen (d), and naked DNA lacZ activity in lung (e), and spleen (f).
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A-G Ziady et al not shown). Organs harvested from mice injected with non-targeted lacZ II DNA complexes (lung, Figure 2c ; spleen, Figure 2d ) as well as those from non-injected mice exhibited no X-gal staining (lung, Figure 2e ; spleen, Figure 2f ). None of the animals had detectable X-gal staining 40 days following injection. No inflammatory infiltrates were observed in any of the surveyed organs at any time point.
Duration of lacZ expression in C57BL/6 and RARb-2lacZ-FVB/N mice C57BL/6 mice injected with 12.5 mg targeted lacZ II DNA exhibited expression in the lung at 4, 10, 21, and 30 days with peak at 10 days, and increasing expression in spleen at 10 and 21 days, which persisted at levels above the background at 30 days ( Figure 3a) . Expression in the liver differed significantly from control values at 4 and 21 days (Po0.05). Expression from nontargeted lacZ II DNA was significantly above background only in the lung at 10 days (Po0.05, Figure 3b ). No lacZ expression was detected in heart in any of the treatment groups (data not shown).
In order to test whether expression diminished because of immune destruction of cells expressing the foreign protein, we studied the time course of lacZ expression in mice transgenic for lacZ driven by the promoter for the retinoic acid receptor (RARb-2lacZ-FVB/N) that is expressed during development and then extinguished. These mice, having expressed lacZ during development, should recognize it as 'self' and fail to mount an immunologic response to it. We reasoned that if immunologic destruction of transfected cells contributes to reduced expression over time, RARb-2lacZ-FVB/N mice would display protracted expression. However, there was a similar temporal course of expression in RARb-2lacZ-FVB/N mice as was observed in C57BL/6 mice ( Figure 3c ). In lung, expression peaked at 4 days after injection and persisted, above background (Po0.05), at 30 days, but fell to background levels at 40 days. Levels in spleen did not significantly differ from background at 4 and 10 days, increased at 21 and 30 days, but returned to background at 40 days. Expression in the liver peaked at 172 361714 779 ILU/mg protein and remained significantly higher than background (Po0.05) through day 21. At days 30-40, expression did not differ from background. Non-targeted lacZ II DNA complexes failed to transfect surveyed tissues in these animals (Figure 3d ). Thus, expression extinguished at 40 days in RARb-2lacZ-FVB/N mice.
hFIX gene transfer in C57BL/6 and Rag-1 À/À C57BL/6j mice Expression of hFIX in the plasma of wild-type C57BL/6 mice treated with targeted complexes peaks at day 4, but remains high at day 10, but is declining by day 16 and disappears by day 21 (Figure 4a ). In immunodeficient Rag-1 À/À C57BL/6j mice, expression was evaluated 2, 10, 20, 30, 40, and 50 days after injection of sec-Rtargeted, nontargeted, or naked pCMV FIX plasmid DNA (Figure 4b ). Human factor IX concentrations were substantial only in animals receiving sec-R-targeted DNA complexes. Peak levels were observed on day 10 (151.1714.2 ng/ml), but factor IX levels persisted up to 30 days at levels above 50 ng/ml. Mice that received nontargeted pCMV FIX DNA complexes produced lowlevel detectable hFIX at 2 days in both C57BL/6 and Rag1 À/À mice and at 10 days in the immunodeficient animals, but expression returned to background levels by 20 days. Two of four immunodeficient animals injected with naked DNA exhibited low-level expression that disappeared by 20 days. These two were the only animals for either reporter gene injected with naked DNA that exhibited transgene expression different from background in any experiment in this study. By day 40, all animals had levels of expression indistinguishable from background.
Polymerase chain reaction amplification of a 714 bp DNA fragment of the hFIX gene revealed that the hFIX gene was present 10 days after dosing in the lungs, livers, and spleens, but not in the hearts of these Rag 1 À/À mice injected with targeted pCMV FIX (Figure 5a and b) . The gene was detected in two of the Host immunity responses to sec-R-mediated gene transfer A-G Ziady et al three animals examined 50 days after injection with sec-R-targeted complexes, although hFIX expression, measured in plasma, had vanished in these animals. Thus, although expression in plasma was not detected at 40 days in these animals, the transgene could still be demonstrated at 50 days in two of three animals. PCR analysis failed to detect the hFIX gene in mice 50 days after injection with naked plasmid DNA. Figure 5b summarizes the results of PCR detection of the hFIX gene.
hFIX expression in mice after repeated administration of sec-R-directed complexes
We compared the efficacy of gene transfer via sec-R after initial and repeated administrations of the C105Y-polylysine-DNA complexes in mice. Mice that received an initial dose of 5 mg targeted hFIX exhibited transgene expression that peaked at between 4 and 10 days ( Figure  6a , black bars), and fell below our limit of detection (dotted line) by day 16. A second dose of targeted complex containing pCMV-hFIX in these immunocompetent animals did not result in subsequent hFIX expression (data not shown). In order to distinguish whether this failure to express following a second dose was due to immune response to the transgene, or immune response to the complex, preventing subsequent transfection, two other groups of mice were studied. These two groups of mice received sec-R-targeted complexes containing identical components to the sec-R-targeted hFIX complexes, but a different plasmid (pCMV lacZ II) in either a low (5 mg, Figure 6a , grey bars) or high (25 mg, Figure 6a , open bars) dose, at days 0 and 16. Following injection of 5 mg sec-R-targeted hFIX at day 40, both pretreated groups exhibited hFIX levels in plasma that did not significantly differ from levels achieved with initial dosing (Figure 6a ). No hFIX expression was observed in pre-dosed groups that subsequently received either 50 ml 1 M NaCl, 5 mg naked DNA, or 5 mg nontargeted hFIX.
When we predosed two groups of C57BL/6 mice with 25 mg of targeted lacZ (high predose) at days 0 and 16, and then administered 5 mg of targeted hFIX at day 40, either i.v. or intranasally (i.n.), different levels of hFIX expression in the plasma were observed depending on the route of administration (Figure 6b ). Peak expression did not differ significantly between i.v. dosing (day 10, 238.87112.5 ng/ml) and i.n. administration (day 10, 97.378.5 ng/ml). We are confident that all the i.v.-dosed animals included in this experiment received the dose, because all had the respiratory pause following dosing that occurs with tail vein injection of B1 M NaCl. Polymerase chain reaction detection of the hFIX gene. DNA extracts from the lungs, livers, spleens, and hearts of Rag-1 À/À C57BL/6j mice injected with 5 mg of either sec-R-targeted or naked pCMV FIX plasmid DNA were PCR amplified with primers specific for hFIX (N ¼ 3 for each group). Heart was included as a negative control, since in none of our preliminary studies was any transgene activity detected in this organ (data not shown). PCR products for lung extracts are shown, 10 and 50 days after injection with sec-R-targeted pCMV FIX (a and b, respectively), and 50 days after injection with naked pCMV FIX plasmid DNA (c). A summary of multi-organ PCR analysis is outlined in panel (d). 
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Transgene expression levels returned to background 27 days following targeted hFIX application by either the i.v. or luminal routes.
Humoral immune response to sec-R-directed DNA complexes and hFIX
We tested plasma from C57BL/6 mice from the two experiments that received multiple doses of targeted complexes for reactivity with the complex components and the hFIX transgene (Exp. 1: i.v. dosing; EXP. 2: i.v. versus i.n. dosing). Figure 7 demonstrates the results observed for the first experiment at 4, 7, 21, and 27 days following the initial injection of targeted or nontargeted DNA complexes or 0.5 M NaCl alone, while Table 2 shows the extent of reaction observed for both experiments by 27 days (following the first dosing of targeted Host immunity responses to sec-R-mediated gene transfer A-G Ziady et al DNA complexes) and 11 days (following the third dosing of targeted DNA complexes). By 27 days, plasma of 14 in 30 immunocompetent animals that received the complexes i.v. reacted with the targeted complex. These animals' plasma also reacted with the C105Y ligand, and the ligand-poly K conjugate, but not with poly K alone, or nontargeted complexes. These same 14 animals continued to exhibit (to the same extent) an immune response to the ligand, conjugate, and targeted DNA complexes 11 days following a third dosing of targeted DNA complexes. Plasma from 0.5 M NaCl, nontargeted complex or naked DNA-injected animals did not react with the ligand, poly K, ligand-poly K conjugate, or nontargeted or targeted DNA complexes (Table 2) . When we compared predosed animals that received the dose i.v. versus i.n. in a second experiment, plasma from five in six animals dosed i.v. reacted with the targeted complex as well as the ligand and the ligandpoly K conjugate 27 days following the second dosing and 11 days following the third dosing. None of the animals predosed i.n. generated detectable amounts of antibody against complex components, while all animals whether dosed i.v. or i.n. generated detectable levels of antibodies to the hFIX transgene.
Discussion
Nonviral gene transfer systems, though quite effective in vitro, often provide only transient low-level gene expression in vivo. 1 We have previously demonstrated that sec-R-directed complexes made with long-chain poly K have extended duration of transgene expression in vivo compared to complexes prepared with shortchain poly K. 8 Here, we show that complexes targeting the sec-R, injected i.v., deliver genes to lung and spleen macrophages. Expression intensity and duration depend upon the presence of the C105Y ligand, and not solely on the compaction of the DNA, since nontargeted complexes give only modest and brief expression above background. Expression from sec-R-targeted complexes lasts for 30 days in some tissues, and is sufficient to produce near-therapeutic levels of the reporter gene hFIX in the plasma of C57BL/6 mice. No inflammatory cellular infiltrate was detected in any transfected tissue at any time point. Thus, the system is efficacious, and appears to have little direct toxicity, though the duration of gene expression is not sufficient for long-term correction of genetic defects. Extending the duration of gene expression is an important goal for future complex development. In this study, we examined whether host immune responses prevent protracted transgene expression or interfere with repeat dosing.
One possibility is that the foreign protein made by the transferred gene might be recognized by the host's immune surveillance, and that protein, or the cells that express it, might be targeted for destruction. This has been reported for adenoviral gene transfer of the lacZ gene to the liver, [12] [13] [14] and seemed a logical hypothesis for the sec-R-directed gene transfer, because many of the cells to which the foreign gene is delivered are macrophages, which are known antigen-presenting cells. The time course of gene expression from sec-R-directed gene transfer is also consistent with this hypothesis, for cytotoxic lymphocytes arise about 2-4 weeks after challenge. Moreover, lacZ delivered via adenoviral vectors is reportedly strongly immunogenic. 13 However, the adenovirus induces an immediate inflammatory response, so the delivery of the foreign protein is in the context of inflammation, and our molecular conjugates provide no such inflammatory context for foreign gene expression. In order to test whether lacZ-expressing cells are destroyed by host CTLs, we studied the duration of its expression in a genetically engineered line of mice in which the bacterial lacZ gene is expressed briefly during development under control of the retinoic acid receptor-B promoter. These mice should recognize this protein as self, but no endogenous lacZ expression should complicate interpretation of delivery of this gene in adult animals. We reasoned that if the reason the expression of lacZ disappears in wild-type mice after about 30 days is that the cells making it are targeted by CTLs and destroyed, then transfected cells in transgenic mice should avoid this fate and expression should be prolonged. However, this was not the case. The pattern of expression was similar in wild-type and transgenic animals, and duration of expression was about 30 days in the transgenic animals, as it was in nontransgenic Host immunity responses to sec-R-mediated gene transfer A-G Ziady et al animals. Given the half-life of macrophages in tissues, if expression continued for the life of the cell, it could last from 3 months (in the case of liver or spleen) to 6 months (in the case of lung). 15 In order to test this hypothesis further, we tested a different transgene, human factor IX. Use of this gene gave us the added advantage of sampling the same animal repeatedly. We found that there was considerable variability from mouse to mouse not only in the intensity of transgene expression, but also in the time course of expression, so that mice with low expression relative to the others in the group on one day might have high expression on another day, and expression could actually increase between days 4 and 10 in an individual animal. Nevertheless, as a group, maximal gene expression was observed on days 4-10 following i.v. injection of the gene transfer complex, and fell thereafter. Peak plasma factor IX levels ranged from 95 to 1274 ng/ml for animals injected with sec-R-directed complexes. Normal blood levels in humans are 1000-3000 ng/ml, and clinical benefit for patients with hemophilia B is reported at levels as low as 1% of normal coagulant activity (or 10-30 ng/ml). 16 Levels 10% of normal are reported to be therapeutic (ie, 100-300 ng/ml), and such levels are routinely achieved by our transfection strategy. The levels achieved from sec-R-directed molecular conjugates are less than those reported following adeno-associated virus gene transfer, 10, 16 but greater than those reportedly achieved by lentiviral gene transfer of human Factor IX in C57BL/6 mice. 17 Duration of gene expression from i.v. injections of naked DNA can be protracted if a high concentration of DNA is injected rapidly in high volume. Zhang et al 18 reported that this method of hydrodynamic transfection results in prolonged transgene expression, especially in liver. However, our low pressure/volume/ concentration method of administration does not produce similar results.
The same temporal pattern of expression, in which levels were maximal at about 4 days, and remained high at 10 days, but were falling by 16-20 days, was observed in both immunocompetent C57BL/6 and in the immunodeficient Rag-1 À/À C57BL/6j animals, which were selected because they fail to mount either antibody or CTL responses to foreign protein, and have been studied previously with hFIX as the transgene. 10 These animals have the additional advantage of reduced antibody response to the circulating human factor IX, which complicates interpretation of expression data when the detection method is by ELISA. The apparent loss of activity in the C57BL/6 mice by day 21 is most likely the result of antibodies to Factor IX protein. In prior studies of the human factor IX gene expressed from adenoassociated viral vectors in Rag-1 À/À mice, factor IX could be detected in the blood for at least 6 months by ELISA, so if our vector had continued expression, we would have expected to detect it in Rag1 À/À animals. 10 The comparable results in C57BL/6 and Rag-1 À/À animals (except for Factor IX antibodies in C57BL/6) suggest that the reduction in circulating transgene is not accounted for by antibody responses to the protein, or by CTL-mediated destruction of the transgene-expressing cells, but by other factors. In support of this observation, we found that the plasmid was still detectable by PCR in lung and spleen 50 days after injection in two of three animals. Owing to the plethora of extracellular nucleases, the continued presence of plasmid DNA at this late time point suggests that the plasmid is most likely inside a protected compartment, probably within the cell, such as the nucleus.
Thus, for both lacZ and factor IX, we find no evidence that the reduction in transgene expression after about 30 days can be ascribed to the host's immune response to transgene-expressing cells. Plasmid DNA is detected in the relevant tissues at 50 days, indicating that it is not all degraded. However, PCR assays are quite sensitive, so it is possible that the DNA is greatly reduced in quantity. This idea is supported by the observation that one sample in each group gave no PCR signal, so much of the DNA might have been degraded at that time. Another possibility is that the CMV promoter is silenced, which has been reported previously in liver. 19 Further studies are needed to distinguish among the alternatives, although CMV promoter silencing, which usually occurs within 1-2 weeks following administration, 20 may not fully explain the decline in expression after 30 days.
Although early reports of the tissue distribution of sec-R indicated that most of the receptor is located in the liver, 3 pronounced X-gal staining was observed in both lung and spleen (mostly in macrophages), while no X-gal staining was obtained in mouse liver, though biochemical evidence of hepatic transfection at a level similar to lung and spleen was obtained. It may be that a larger number of cells are transfected in the liver than in lung or spleen, but each to a lesser extent, such that fewer lacZ molecules are produced per transfected cell. Our chemiluminescent assay of lacZ activity can detect 10-fold fewer molecules per cell (B4000) than are required to achieved X-gal staining. 20 If each transfected liver cell produces fewer molecules of lacZ than the threshold required for X-gal staining, similar overall organ levels of transgene enzyme activity could be observed in the liver and spleen without X-gal-positive cells in liver, while they are present in spleen. This notion is supported by data from HuH7 cells in vitro, where chemiluminescent activity could be measured in transfections with as little as 0.01 ng DNA per well, while X-gal staining required at least 10 ng DNA.
Although high-volume hydrodynamic injections result in expression predominantly in the liver, 18 ,21 our method of low volume/low pressure injection is not expected to deliver complexes preferentially to the liver, though hepatic delivery of our complexes is achieved. Alternatively, it is possible that transfection of monocytes occurs in the circulation, and then these cells migrate into the various tissues where they take up residence and differentiate into macrophages.
In human hepatoma cells transfected in vitro with sec-R-directed molecular conjugates made with longchain poly K (identical to those used here in vivo), peak expression is also delayed 4-10 days after transfection. 2 Therefore, the temporal pattern of expression observed in vivo are similar to that seen in vitro. In addition, receptor access is only one of the events required for transgene expression. The complex must be taken up, and once inside the cell the DNA must reach the nucleus and be expressed. It is postulated that the sec-R ordinarily directs its cargo to lysosomes for degradation, 7 and this trafficking may be inimical to gene transfer. Gene transfer may thus be less in cells with efficient lysosomal routing of receptor cargo. Although DNA Host immunity responses to sec-R-mediated gene transfer A-G Ziady et al compaction retards the degradation of plasmid DNA, 8 it does not prevent it, and lysosomal enzymes probably eventually destroy the plasmid if it does not escape and enter the nucleus.
Although it was not the goal of this study to assess the toxicity of the complexes, we can comment on the mortality and on the histology of the tissue sections retrieved from them. When i.v. injections with B1 M NaCl were limited to 50 ml volume, there was no mortality following tail vein injection of the complex in the hands of an experienced operator, though all the injected animals had a brief respiratory pause following injection. Review of histologic sections from the lung, liver, and spleen retrieved at various time points (4, 10, 21, and 30 days) after injection revealed no inflammatory infiltrate in the tissues of animals treated with sec-Rdirected complexes. These tissues could not be distinguished from those of control animals that were uninjected or those that received either naked DNA or nontargeted complexes by observers unaware of the treatment assignment of the mice. This contrasts with reports of adenoviral gene transfer in which cellular infiltrates about transfected cells are regularly observed. [12] [13] 22 The failure of the complex to induce a 'danger' signal in the vicinity of the transfected cells may reduce the host's immune response to the transgene.
In this study, we also tested whether repeat administration of sec-R-directed complexes is feasible. If the complexes themselves provoke an antibody response, gene delivery from subsequent administrations of the complex may be compromised, and expression may be less. In prior studies with molecular conjugates targeting the polymeric immunoglobulin receptor, gene expression was reduced by 75% at the third i.v. administration of the complex, and this reduction was associated with serum antibodies directed against the protein ligand portion of the complex, a Fab antibody fragment. 23 No antibody was detected against the poly K or DNA portions of the complex. We tested whether sec-R-directed complexes provoke antibody responses that are associated with reduced gene transfer and expression. In order to avoid the issue of immune response to the transgene itself, we administered sec-R-targeted complexes containing an irrelevant transgene for two doses 3 weeks apart and then administered complexes containing the transgene of interest, in this case hFIX. If neutralizing antibodies had developed to the complexes, levels of hFIX in the plasma should be reduced compared to mice that had never received complexes before. However, plasma hFIX levels were at least as high in animals treated with sec-Rdirected complexes twice before as they were in naïve mice. Therefore, transgene expression from sec-R-directed complexes is not impaired by their prior administration. However, when we tested the serum of these animals for antibodies directed against the complex, about half of the mice were positive, defined as more than 3 standard deviations above values obtained in plasma from untreated mice. Most of these mice gave a very low signal, so antibody production may have been minimal. Moreover, when the hFIX levels obtained in mice that had antibodies were compared with those from mice which did not, no difference was seen. Thus, either the antibodies were present at such low levels that they did not affect gene transfer, or they were directed against other portions of the C105Y peptide and did not affect receptor binding, or the antibodies themselves may have redirected the complexes, for example, to cells with an Fc receptor, and allowed continued transgene expression by this means. As was the case for the polymeric-immunoglobulin-receptor-directed complexes, 23 the antibodies were directed at the ligand, not at the poly K or the DNA itself. However, in contrast to the levels of antibody detected in animals dosed with complexes directed at the polymeric immunoglobulin receptor, which were detectable in 1/30 000 dilutions of serum in some mice, 23 most animals dosed with Sec-R-directed complexes had antibody signals that were not different from background even at 1/10 dilution. This observation supports the idea that the C105Y peptide is only weakly immunogenic. Although antibodies were detected (at low levels) in half of the animals that received sec-R-targeted complexes i.v., they were not observed at all in the plasma of 10 mice treated three times at 3-week intervals via the i.n. route, either in plasma or in bronchoalveolar lavage fluid (measured on the final day of the experiment). Delivery via the i.n. route gave mean plasma levels of hFIX comparable to those obtained with i.v. administration, though expression level variability between animals was decreased. Given the modest dose administered and the lack of optimization of the dosing for the i.n. route, these data suggest that airway administration may also be a viable route for repeat administration of sec-R-directed gene transfer complexes. 6 The sec-R-directed gene transfer system therefore has the advantages of cellular specificity, moderate initial duration of expression, and good efficacy, with little evident toxicity. The same ligands can be employed for rodents and humans facilitating preclinical testing. However, the system must be improved so that complexes are stable in normal saline and tissue fluids, do not require high salt concentrations to retain their integrity, and need not be freshly prepared by an expert just prior to injection. The development and characterization of such second-generation complexes is in progress. 24 Also, our data suggest that re-engineering the plasmid DNA construct to eliminate promoters prone to silencing (eg, by substitution of a eukaryotic promoter) might well extend the duration of expression. Antibody responses to the complexes, when they occur, were low titer and did not prevent subsequent transfection with sec-R-targeted complexes. This is encouraging for the future production of efficacious complexes that are targeted with this ligand and stable in normal saline.
Materials and methods

Materials
DNA-modifying enzymes, nucleotides, and 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (X-gal) were purchased from Boehringer Mannheim (Indianapolis, IN, USA). LacZ luminescent activity was measured using reagents obtained from Tropix (Bedford, MA, USA). Poly K was obtained from Sigma Chemical Co. (St Louis, MO, USA) and LC sulfo-N-succinimidyl-3-(2-pyridyldithio) proprionate (sulfo-LC-SPDP) was purchased from Pierce Chemical Co. (Rockford, IL, USA). Bradford protein assay reagents were obtained from Bio-Rad (Richmond, CA, USA). Peptide C105Y (CS IPPEV KFNKP FVYLI) was produced by solid-phase synthesis, purified, and
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Construction of the protein portion of DNA complexes
Peptide C105Y was covalently linked to poly K (average poly K length 256 a.a. (53.7 kDa)) using the heterobifunctional crosslinking reagent sulfo-LC SPDP as previously described. 9 This chain length was selected based on earlier studies showing that the longer the chain length of poly K incorporated into the complex, the greater the duration of expression. The molar ratio of sulfo-LC SPDP to lysine residues was 1:10 in the reaction mix. In subsequent nuclear magnetic resonance (NMR) spectroscopy, performed as previously described, 9 this ratio was determined to give an actual substitution rate of about 8.3%. Receptor ligand C105Y was then added at a molar ratio 1:200 (ligand/lysine residue). Subsequent NMR spectroscopy determined that the actual substitution of ligands per lysine residue was 0.38%. This degree of substitution was used based on earlier studies identifying it as the most favorable for long-term gene expression.
Reporter genes and plasmid preparation Two plasmids coding for two different reporter genes were used. The plasmids pCMV lacZ II 25 and pCMV FIX (obtained from Dr Jose Perales, Case Western Reserve University, Cleveland, OH, USA) contain the cytomegalovirus (CMV) promoter ligated to the bacterial lacZ and the hFIX genes, respectively. The pCMV FIX plasmid contains a leader sequence for secretion of the transgene. The plasmids were grown in E. coli DH5a, extracted, and purified twice on a cesium chloride density gradient. 26 Identity of the plasmids was confirmed by restriction endonuclease digestion, and purity was established by 1.0% agarose gel electrophoresis. The sizes of the plasmids are: pCMV lacZ II, 10.8 kB; and pCMV FIX, 5.4 kB.
Preparation of C105Y peptide-based DNA complexes
The carrier DNA complexes were prepared as previously described. 8, 9 Unsubstituted or ligand-substituted poly K was mixed with plasmid DNA, so that there were a sufficient number of lysine residues to completely neutralize the phosphate group charges on each DNA plasmid, that is, at a 1:1 charge ratio. At this charge ratio, pCMV lacZ II and pCMV FIX DNA complexes were calculated to contain 22 and 11 ligands per complex, respectively. The concentration of NaCl was gradually raised by addition of aliquots of 5 M NaCl. When complexes unimolecular with respect to DNA were formed, the concentration of NaCl in the suspension medium was 1-1.1 M. With the exception of the compacted pCMV lacZ II DNA complex dose-response experiment, the final DNA concentration was 200 mg/ ml. For the dose-response experiment, DNA complexes were diluted or concentrated to achieve desired DNA concentrations.
Structure of the condensed DNA complexes
Compacted DNA complexes were imaged by electron microscopy (EM) and atomic force microscopy (AFM) as previously described. 2, 8, 9 For the pCMV FIX plasmid, complex diameter averaged 1770.9 nm by EM, while by AFM complex sizes averaged 2571.9 nm. For the pCMV lacZ II plasmid, complex diameter averaged 2371.2 nm by EM. To obtain these figures, at least 50 complexes per plasmid were measured on the EM grids.
Assay for lacZ activity (galacto-light assay)
For in vivo experiments, organs of animals were immediately frozen in liquid nitrogen and stored at À801C until homogenized in 1 ml lysis solutions containing 12 mM leupeptin, 20 mM PMSF, and 0.1% Triton X-100 in PBS. Homogenates were then incubated at 481C for 1 h to inactivate endogenous galactosidase activity. Triplicate aliquots (20 ml each) were added to 200 ml of the reaction buffer and incubated at room temperature for 1 h. A volume of 300 ml of light emission accelerator (Tropix, Bedford, MA, USA) was then added and the reaction monitored for 10 s in a luminometer.
Bacterial lacZ expression localization in mice
Individual cells expressing lacZ were identified as previously described. 25 Briefly, C57BL/6 and RARb2lacZ-FVB/N mice were injected with targeted and nontargeted pCMV lacZ II DNA complexes and tissues collected 4, 25, and 40 days after injection. Harvested tissues were thoroughly washed with PBS, fixed with a solution of 0.5% glutaraldehyde in PBS for 5 min, washed again, and incubated in a solution containing 0.5% X-gal for 4 h at 371C. Tissues were then fixed in 2% paraformaldehyde for at least 48 h, then embedded in paraffin and sectioned at 0.5 mm intervals and mounted on glass slides. Adjacent sections were then lightly counterstained with nuclear fast red (NFR) covered with coverslips. Blue-colored cells were identified and photographed through an inverted light microscope by an investigator unaware of the treatment assignment of the mice.
Cell culture and lacZ expression in hepatocytes in vitro
To determine whether lacZ chemiluminescent activity may be achieved in the absence of X-gal staining, we used HuH7 human hepatoma cells that were grown and maintained in 24-well plates as previously described. 9 When cells reached 50% confluency, they were incubated with 100, 10, 1, 0.1, or 0.01 ng of pCMV lacZ II DNA complexed with lipofectamine (Invitrogen Corp., Carlsbad, CA, USA) for 5 h (n ¼ 8 wells for each concentration), then washed and incubated with growth media. At 2 days following transfection, four wells from each DNA concentration were lysed and assayed for lacZ activity with Galactont reagent, while four wells were stained with the X-gal reagent. For each sample, cells were counted by a hemocytometer. Data were normalized to activity per mg protein or staining per 100 000 cells.
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Sec-R-targeted complex administration in mice
Mice, originally obtained from The Jackson Laboratory (Bar Harbor, ME, USA), were bred and maintained in a sterile environment in house. SEC-R-directed DNA complexes examined in vitro were injected into the tail veins of anesthetized adult C57BL/6 mice (6-8 weeks old, B25 g). Injections were performed over 1-3 min without excess pressure in a volume no greater than 50 ml. For the determination of dose dependence using the pCMV lacZ II plasmid, animals were injected with complexes containing either 2.5, 12.5, or 25 mg (in 50 ml) of DNA in targeted complexes and their organs harvested and assayed for lacZ activity 4 days after injection. For experiments involving duration of expression, complexes containing 12.5 mg targeted pCMV lacZ II DNA in 50 ml were injected into the tail vein of either C57BL/6 mice or RARb-2lacZ-FVB/N mice, a generous gift from Dr Jeff Whitsett, and organs harvested at intervals thereafter and processed either for X-gal staining and histochemistry or for lacZ activity. The RARb-2lacZ-FVB/N mice are transgenic for the lacZ gene driven by the retinoic acid receptor b-2 promoter, which is expressed during development but is not active during adulthood. For these experiments, controls included animals injected with 5 mg of free pCMV lacZ II DNA; animals injected with complexes of 5 mg of pCMV lacZ II condensed with poly K (no ligand); and noninjected animals. Organs were harvested at 4, 10, 21, 30, and 40 days and assayed for lacZ expression.
For experiments with hFIX as transgene, 5 mg pCMV FIX DNA was injected i.v. via the tail vein. Due to the smaller size of the plasmid, a comparable number of particles (to pCMV lacZ II complexes) was injected. In hFIX experiments, blood was taken at intervals from the orbital sinus or the tail vein for determination of hFIX levels and/or antibody responses. Both C57BL/6 and Rag-1 À/À mice were studied in experiments with hFIX. Blood was drawn following administration on days 2, 4, 10, 16, and 21 for the C57BL/6 and days 2, 10, 20, 30, 40, and 50 for the Rag-1 À/À mice, and assayed for hFIX levels. The longer time course was designed to test whether expression would extinguish in the Rag-1 À/À C57BL/6j animals, which have severe deficiency of both the cellular and humoral immune response, and fail to produce functional B or T cells and do not mount antibody or cell-mediated immune responses to hFIX. In addition to examining hFIX levels in the Rag-1 À/À mice, we also collected organs from these animals for PCR detection of vector DNA (see below). For hFIX experiments with C57BL/6 and Rag-1 À/À mice, treatment groups included: mice injected with 5 mg (in 50 ml of 1 M NaCl) of targeted pCMV FIX DNA complexes; animals injected with 5 mg of nontargeted FIX DNA complexes; and animals injected with 5 mg FIX naked DNA. Blood was drawn at 2, 10, 20, 30, 40, and 50 days after injection and assayed for hFIX.
For experiments to test the ability to re-administer the complexes, three groups of C57BL/6 mice were used. The first (virgin-dosed group, n ¼ 14) received 5 mg targeted hFIX complexes on days 0 and 16. The second (low predose group, n ¼ 12) received 5 mg targeted lacZ on days 0 and 16 and 5 mg targeted hFIX complexes at day 40. A third group (high predose group, n ¼ 4) received 25 mg targeted lacZ on days 0 and 16 and 5 mg targeted hFIX complexes at day 40. Three groups of control mice (n ¼ 5 each) that were dosed with 25 mg targeted lacZ at days 0 and 16 received 50 ml 0.5 M NaCl, or 5 mg nontargeted hFIX complexes at day 40. Generation of antibodies against the transgene, C105Y ligand, poly K-C105Y conjugate, and/or fully formed targeted DNA complexes was assessed by ELISA at days 7, 14, 21, and 27. Human factor IX expression was measured in plasma 2 and 4 days following administration of targeted hFIX complexes. For animals that received virgin doses of targeted hFIX, hFIX expression was also assessed at days 8, 10, and 16. To evaluate the effect of the route of administration, two groups of C57BL/6 mice received 25 mg of targeted lacZ complexes either i.v. (n ¼ 6) or i.n. (n ¼ 10) at days 0 and 16. We had previously shown that both of these delivery routes result in gene expression in the lung, though for the i.v. route expression is predominantly in macrophages, 8 whereas by the i.n. route epithelial cells are the primary target cell. 6 On day 40, each respective group received 5 mg targeted hFIX either i.v. or i.n. Generation of antibodies against the various components of the DNA complex was assessed by ELISA at days 7, 14, 21, and 27. Human factor IX was measured in plasma 2, 10, and 27 days following administration of targeted hFIX complexes.
Number of samples (n, shown in figure legends) denotes the number of animals injected with the various reagents. The murine research protocol was reviewed and approved by the Case Western Reserve University Institutional Animal Care and Use Committee.
Assay for hFIX
Whole blood drawn from treated and untreated animals (100 ml) was treated with 10% sodium citrate (to prevent coagulation) and then centrifuged to isolate plasma, which was stored at À201C until assay. Aliquots were assayed for the presence of hFIX by ELISA. Standards, ranging in concentration from 1 to 1000 ng/ml, were prepared using purified hFIX (American Diagnostica Inc., Greenwich, CT, USA). ELISA plates were coated with the capturing monoclonal mouse IgG derived antihFIX (Hematological Tech., Eessex, VT, USA) and incubated at 41C overnight. Plates were then thoroughly rinsed with 0.1% Tween-20 PBS and blocked with 100 ml of 10% fetal calf serum (FCS) in RPMI media (Gibco) for 1 h. Standards as well as plasma collected (diluted 1:10) from treated mice were then added (50 ml volume) and incubated at room temperature for 2 h. Following three stringent washes, 50 ml of primary antibody (rabbit IgG-derived polyclonal anti-hFIX (Cal. Biotech.)) diluted in 10% FCS RPMI 1:1000 was added to the wells and incubated at room temperature for 1 h. Following three washes, 50 ml of a 1:2000 dilution in 10% FCS RPMI of the secondary antibody, a goat anti-rabbit IgG conjugated to horseradish peroxidase (Boehringer Mannheim), was added and incubated for 1 h at room temperature. After three washes, samples were incubated for 15 min with tetramethyl benzidine dihydrochloride (TMBD) and horseradish peroxidase activity measured at OD 450 nm . The antibodies used for this ELISA do not crossreact with mouse coagulation factor IX. All assays were carried out in duplicate, and the results are expressed as ng of hFIX per ml of mouse plasma.
Host immunity responses to sec-R-mediated gene transfer A-G Ziady et al PCR detection of pCMV FIX plasmid DNA in Rag-1 À/À C57BL/6j mice Genomic DNA (B1-10 mg) extracted from the lungs, livers, spleens, and hearts of mice 10 or 50 days after injection with targeted pCMV FIX DNA complexes, as well as controls injected with either naked or non-targeted pCMV FIX DNA complexes, was amplified through 30 cycles with primers predicted to produce a 714 bp fragment of the hFIX gene, as previously described. 27 The primers used to amplify this fragment of hFIX do not hybridize to the mouse coagulation factor IX gene. Products were analyzed by agarose gel electrophoresis (2%).
Assay for serologic response against DNA complexes and the transgene Antibodies generated against the transgene, C105Y ligand, poly K-C105Y conjugate, and targeted complexes were assessed by ELISA at days 7, 14, 21, and 27 (complex components only) for doses of targeted complexes administered at days 0 and 16. Aliquots (50 ml) of newly prepared DNA complex (5 mg DNA), equivalent amounts of individual components of the complexes, or 50 ng of purified hFIX, were incubated overnight at 41C to coat each well of a 96-well microtiter plate. The following day, the wells were washed three times with 1% bovine serum albumin, then blocked for 2 h at 371C with 5% bovine serum albumin. After a one-time wash, 100 ml of plasma from each mouse at a dilution in phosphate-buffered saline of 1:10 was incubated in the wells for 2 h at 371C. This was followed by three washes and the addition of polyclonal goat antibody against mouse kappa (light) chains conjugated to alkaline phosphatase (Sigma Immunochemical Company, St Louis, MO, USA) at 1:1000 in PBS, pH 7.4, with 1% bovine serum albumin. After three washes, 1 mg/ml of r-nitrophenyl phosphate, disodium (rNPP) (Sigma Chemical Company, St Louis, MO, USA) in glycine buffer was added to develop the reaction, and serial spectrophotometric readings at 410 nm were taken. Plasma was scored positive if OD units exceeded the mean blank (average OD for control animals) plus three times the standard deviation (3 SD).
Statistical analysis
Data are expressed as the mean7standard error of the mean (SEM) and are evaluated by rank analysis with ANOVA or paired t-test as appropriate. 28 
